STOCK TITAN

NeuroOne Medical Technologies Corporation - NMTC STOCK NEWS

Welcome to our dedicated page for NeuroOne Medical Technologies Corporation news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on NeuroOne Medical Technologies Corporation stock.

NeuroOne Medical Technologies Corporation (symbol: NMTC) is a cutting-edge medical technology company based in Eden Prairie, Minnesota. The company specializes in the development and commercialization of innovative thin-film electrode technology designed for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, brain stimulation, and ablation solutions. These technologies are particularly beneficial for patients suffering from a variety of brain-related disorders, including epilepsy, Parkinson's disease, dystonia, and essential tremors.

NeuroOne's core business revolves around creating comprehensive neuromodulation solutions that integrate cEEG and sEEG recording, monitoring, brain stimulation, and ablation. This focus has led to notable advancements such as the Evo® sEEG system, which is the first FDA-cleared thin-film sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue, with the added benefit of temperature control.

The company is actively involved in various exciting projects and partnerships. One of their key initiatives is the Drug Delivery Program, which is expected to achieve several important milestones in the near future. Additionally, NeuroOne is continuously enhancing its product portfolio to better serve its target patient population.

Financially, NeuroOne has provided promising updates for the second quarter of the fiscal year 2024. The company’s recent business highlights include significant progress in their OneRF™ Ablation System and Spinal Cord Stimulation Program. Investors and interested parties can access more detailed financial results and updates through their quarterly conference calls and webcasts.

For more information or to get in touch with NeuroOne, please contact them at 800-631-4030 or email ir@nmtc1.com.

Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will showcase its innovative technology at two investor conferences in March 2022. The Oppenheimer 32nd Annual Virtual Healthcare Conference is scheduled for March 16, 2022, at 1:20 p.m. ET, while the 34th Annual ROTH Conference will take place from March 13-15, 2022, in Laguna Niguel, California. CEO Dave Rosa will discuss the company's Evo® Cortical Electrodes aimed at improving care for neurological disorders. The firm is also exploring advancements in artificial intelligence and machine learning.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
conferences
-
Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced successful completion of initial bench top testing on its thin film electrode technology, showing potential for chronic stimulation use over approximately 5 years. The tests confirmed the electrodes' durability and performance at higher stimulation levels. CEO Dave Rosa highlighted the opportunity for expansion into treatment areas like epilepsy and chronic back pain. The market potential for related technologies is estimated at over $10 billion. The company is advancing its electrode technologies for various neurological disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
none
-
Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its Q1 fiscal 2022 results, reporting product revenue of $34,000, down from $71,000 in Q1 2021. Collaboration revenue also decreased from $22,000 to $6,000. Operating expenses rose to $2.8 million, with a net loss of $2.8 million, compared to $2 million the previous year. The company strengthened its financial position through a public offering, generating $13.35 million. Key developments include FDA clearance requests for its Evo sEEG Electrode, with expected commercial readiness and milestone payments from Zimmer Biomet.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.75%
Tags
Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced successful pre-clinical long-term testing of its thin film electrode technology, showing reliability in recording electrical activity for over 5 years. The accelerated aging tests confirmed the electrodes' ability to withstand environmental challenges, a key issue in neurotechnology. CEO Dave Rosa highlighted the potential for these electrodes in treating conditions like epilepsy and Parkinson's disease, and the company aims to explore research market opportunities and strategic partnerships in this field. NeuroOne's therapeutic electrode technologies target over $10 billion in addressable markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.07%
Tags
none
-
Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on February 14, 2022, at 4:30 PM Eastern Time to discuss its first-quarter fiscal results for 2022, which ended on December 31, 2021. This call is part of the company’s commitment to improving surgical care for patients with neurological disorders. Interested parties can access the call via toll-free numbers or the provided webcast link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has appointed Chad Wilhelmy as Vice President of Quality Control and Regulatory Affairs. With 20 years of experience in the medical device industry, Wilhelmy aims to enhance the company's quality systems and regulatory foundations. As part of his employment, he received an option to purchase 50,000 shares at an exercise price of $1.95 per share. CEO Dave Rosa expressed confidence in Wilhelmy's experience to support the company's growth, focusing on improving surgical care for neurological disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.87%
Tags
management
Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is featured on The Medical Alley Podcast, highlighting their innovations in neurological care. CEO Dave Rosa discusses the company's development of high-definition film electrodes aimed at treating conditions like epilepsy. The podcast aims to enhance public awareness about NeuroOne's commitment to improving surgical options and outcomes for patients with neurological disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
none
-
Rhea-AI Summary

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) reported its fourth quarter and full fiscal year 2021 financial results. The Company achieved product revenues of $48,000 and $178,000 for the quarter and year, respectively, compared to no product revenue in the prior year. Notably, collaboration revenue declined significantly to $5,000 for Q4 and $65,000 for the full year from $1.9 million in FY 2020. Operating expenses totaled $10.2 million for the year, resulting in a net loss of $9.9 million. The Company closed a public offering, raising $13.35 million to support product launches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
-
Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on December 15, 2021, at 9:00 AM Eastern Time to discuss its financial results for the fourth quarter and fiscal year ended September 30, 2021. Interested participants can call 888-506-0062 (toll-free) or 973-528-0011 (international) with access code 527216. The call can also be accessed through a webcast, with replay available post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.24%
Tags
conferences earnings
Rhea-AI Summary

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a public offering of 3,750,000 shares of common stock priced at $3.20 per share. The offering is expected to yield approximately $12.0 million in gross proceeds before expenses and is scheduled to close by October 15, 2021. The company has granted underwriters a 30-day option to purchase an additional 562,500 shares. Proceeds will be utilized for working capital and general corporate purposes. The offering is made under the effective shelf registration statement filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.37%
Tags

FAQ

What is the current stock price of NeuroOne Medical Technologies Corporation (NMTC)?

The current stock price of NeuroOne Medical Technologies Corporation (NMTC) is $0.949 as of November 4, 2024.

What is the market cap of NeuroOne Medical Technologies Corporation (NMTC)?

The market cap of NeuroOne Medical Technologies Corporation (NMTC) is approximately 29.1M.

What does NeuroOne Medical Technologies Corporation focus on?

NeuroOne focuses on developing and commercializing thin-film electrode technology for cEEG and sEEG recording, brain stimulation, and ablation solutions.

Where is NeuroOne Medical Technologies Corporation based?

The company is based in Eden Prairie, Minnesota.

What disorders does NeuroOne's technology address?

Their technology addresses brain-related disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors.

What is the Evo® sEEG system?

The Evo® sEEG system is an FDA-cleared thin-film sEEG-guided RF system that can record electrical activity and ablate nervous tissue with temperature control.

What are some of NeuroOne's current projects?

Current projects include the Drug Delivery Program and the OneRF™ Ablation System, among others.

How can I contact NeuroOne Medical Technologies Corporation?

You can contact them at 800-631-4030 or email ir@nmtc1.com.

What recent financial updates has NeuroOne provided?

In the second quarter of fiscal year 2024, NeuroOne reported progress in the OneRF™ Ablation System and Spinal Cord Stimulation Program.

What type of medical technology does NeuroOne specialize in?

NeuroOne specializes in neuromodulation technology, particularly thin-film electrode technology for cEEG and sEEG recording, brain stimulation, and ablation.

What is the significance of the FDA clearance for NeuroOne's technology?

The FDA clearance for the Evo® sEEG system signifies the approval and safety of the technology for medical use, affirming its efficacy in recording electrical activity and ablating nervous tissue.

Where can I find more detailed financial results and updates about NeuroOne?

Detailed financial results and updates can be accessed through quarterly conference calls and webcasts organized by the company.

NeuroOne Medical Technologies Corporation

Nasdaq:NMTC

NMTC Rankings

NMTC Stock Data

29.12M
30.81M
10.22%
19.62%
0.42%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
EDEN PRAIRIE